Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Fusion Pharmaceuticals

Explore full profile

Targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers

Hamilton, CanadaFounded 2014Biotech & Life Sciences
Valuation $1.68B Market cap · 2024
Revenue $1–10M Latest reported FY

About Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing next-generation precision medicines for cancer treatment. The company operates in the biopharmaceutical market, focusing on creating innovative radiotherapeutics that target multiple tumor types. Fusion Pharmaceuticals serves cancer patients and healthcare providers, aiming to improve patient outcomes and quality of life. The business model revolves around research and development, leveraging proprietary linker technology to enhance the safety and efficacy of their treatments. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of their therapeutic products. The company is a spin-out from the Centre for Probe Development and Commercialization (CPDC), which provides it with a robust supply chain and extensive expertise in manufacturing. Fusion Pharmaceuticals is committed to pushing the boundaries of science to offer revolutionary cancer treatments.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2014
Headquarters
Hamilton, Canada
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • FACIT (Fight Against Cancer Innovation Trust)

Series A12 investors entered at this stage

  • Johnson & Johnson Development Corporation
  • Johnson & Johnson Innovation
  • TPG Biotech
  • Genesys Capital
  • HealthCap
  • Varian Medical Systems
  • Adams Street Partners
  • Seroba Life Sciences
  • OrbiMed
  • Pivotal Life Sciences
  • Rock Springs Capital
  • Perceptive Advisors

Series B and later6 investors entered at this stage

  • Perceptive Advisors
  • Rock Springs Capital
  • Pivotal Life Sciences
  • McMaster University
  • OrbiMed
  • Centre For Probe Development And Commercialization
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States50%
🇨🇦 Canada42.3%
🇮🇳 India5.8%
🇪🇬 Egypt1.9%
4 countries shown
Web traffic by country
4.1K monthly visits
across markets
🇺🇸 United States61%
🇨🇦 Canada22%
🇮🇳 India17.1%
Top 3 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Fusion Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fusion Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.